Table 2.

Current status of various metabolic pathway inhibitors.

Inhibition of pathways	Inhibitor	Research status
Inhibits hexose kinase	2-DG	Phase I clinical trial [87]
Inhibits PKM2	Shikonin	In vitro experiments [88]
	HA344	In vitro experiments [89]
Inhibits PDK	DCA	Phase II clinical trial [90]
Inhibits HIF-1α	PX-478	Phase I clinical trial [91]
	EZN-2968	Phase I clinical trial [92]
Inhibits HIF-2α	Belzutifan	Phase II clinical trial [93]
Inhibits PI3K	CYH33	Phase I clinical trial [94]
Inhibits AKT	MK-2206	Phase II clinical trial [95]
Inhibits mTOR	Temsirolimus	Phase II clinical trial [96]
	Everolimus	Phase II clinical trial [97]
	Ridaforolimus	Phase I clinical trial [98]
	Sapanisertib	Phase II clinical trial [99]
	AZD8055	Phase I clinical trial [100]